20 results about "Isotonic Solutions" patented technology

A method of preparing sterile human placental allografts by providing a human placental tissue from a donor within 24 hours to 72 hours post-childbirth; removing any visible blood, blood clots, and / or blood components from the human placental tissue without scraping or scrubbing the human placental tissue to preserve structural integrity of the human placental tissue; washing the human placental tissue in an isotonic solution while maintaining the structural integrity of the human placental tissue; dehydrating the human placental tissue thereby forming the dehydrated human placental tissue; resizing the dehydrated human placental tissue into dehydrated human placental tissue portions having predetermined sizes; and sterilizing the dehydrated human placental tissue portions of step (e) thereby forming the sterile human placental allograft. Also disclosed is a sterile human placental allograft produced by the method.

The invention relates to a method for preparing all-female fingerlings of land-sealed Malus salicina by utilizing hydrostatic pressure, and belongs to the technical field of aquaculture. The method for preparing the all-female fingerling of the land-sealed Malus salicina by utilizing the hydrostatic pressure comprises the following steps: taking eggs from female land-sealed Malus salicina in a mature period, soaking the obtained eggs in an isotonic solution for 5-10 minutes, performing hydrostatic pressure treatment in the isotonic solution, taking out the obtained parthenogenetic development eggs, and putting the eggs into a hatching nest for hatching. The method is short in time consumption, can meet the requirement for one-time mass production of all-female fry of the Malus salicina, has the advantages of being low in production cost, easy to operate, time-saving, labor-saving and efficient, and can achieve the effect that the all-female rate of the hatched parthenogenetic fry is 100%.

The invention belongs to the technical field of frozen slicing, and particularly relates to an animal lung tissue frozen embedding and slicing and space transcriptome sequencing method. In the first aspect, the animal lung tissue freezing and embedding method is provided and comprises the following steps that blood in animal lungs is replaced with first perfusate, and the first perfusate is selected from a first isotonic solution; liquid in the lung is replaced with second perfusate, the perfused lung is obtained, and the second perfusate comprises OCT and a second isotonic solution; and embedding the perfusion lung by adopting OCT (optical coherence tomography), and then quickly freezing. The lung is perfused with the perfusate formed by mixing OCT and the buffer solution, damage to the space structure and form can be reduced, and the tissue slice with the complete internal structure is obtained. Through experimental tests of different thicknesses of perfused lung tissue slices, the slices with the thickness of 10 microns are successfully obtained, in a space transcriptome experiment, the state that most cells belong to monolayer cells is achieved, and the data quality is improved.

The invention discloses a PDRNamp and a method for preparing the PDRNamp. The invention discloses EGT eye wash as well as a preparation method and application thereof, and belongs to the technical field of eye care products. The eye wash is prepared from the following active components in percentage by mass: 0.001 to 0.01 percent of PDRN, 0.03 to 0.1 percent of EGT (Ergothioneine), sodium hyaluronate, sodium chloride, taurine and the like, wherein the mass percent of the PDRN is 0.001 to 0.01 percent, and the mass percent of the EGT is 0.03 to 0.1 percent. Through the synergistic effect of PDRN and EGT, the product has excellent cornea repairing capacity and a powerful anti-oxidation function at the same time, and the moisturizing and soothing effects are enhanced by compounding sodium hyaluronate and taurine. The obtained eye washing liquid is an isotonic solution with neutral pH, is mild and non-irritating, does not contain preservatives, can effectively achieve multiple nursing effects of eye cleaning, moisturizing, repairing, anti-inflammatory and anti-oxidation, and is suitable for relieving xerophthalmia, assisting cornea repair and daily anti-oxidation nursing of eyes.

The invention discloses an irinotecan and afatinib maleate co-loaded liposome preparation as well as a preparation method and application thereof, irinotecan and afatinib maleate are taken as effective components of the liposome, and the liposome comprises a liposome carrier, an inner water phase positioned in a liposome membrane and an outer water phase positioned outside the liposome membrane; the irinotecan and the afatinib maleate are encapsulated in the inner water phase; the inner water phase comprises an ammonium salt aqueous solution, and an ammonium salt gradient exists between the inner water phase in the liposome membrane and the outer water phase outside the liposome membrane; the outer water phase is a physiological isotonic solution. According to the present invention, the research results show that the irinotecan and afatinib maleate co-carrying liposome can simultaneously deliver the two drugs with the synergistic ratio into the same tumor cell compared to the irinotecan single drug liposome and the afatinib maleate single drug liposome so as to maximize the synergistic effect of the drugs, and significantly improve the anti-tumor effect;

An ex vivo test system 10 is constituted of a fluid circuit that circulates a prescribed circulation liquid by simulating the blood circulation state of a human body, and comprises a circulation liquid maintenance unit 17 that maintains, in the same manner as the blood environment in vivo, chemical factors in the circulation liquid, which affect the performance evaluation of a test object S. The circulation liquid maintenance unit 17 comprises: a replenishing liquid unit 23 that maintains the chloride ion concentration and protein concentration of the circulation liquid at desired values by injecting a replenishing liquid composed of an electrolyte-free isotonic solution into the fluid circuit; and a carbon dioxide supply unit 24 that maintains the pH of the circulation liquid at a desired value by supplying carbon dioxide into the fluid circuit, the state of the circulation liquid being maintained while compensating for the effect of moisture loss during circulation of the circulation liquid.

A method of preparing sterile human placental allografts by providing a human placental tissue from a donor within 24 hours to 72 hours post-childbirth; removing any visible blood, blood clots, and / or blood components from the human placental tissue without scraping or scrubbing the human placental tissue to preserve structural integrity of the human placental tissue; washing the human placental tissue in an isotonic solution while maintaining the structural integrity of the human placental tissue; dehydrating the human placental tissue thereby forming the dehydrated human placental tissue; resizing the dehydrated human placental tissue into dehydrated human placental tissue portions having predetermined sizes; and sterilizing the dehydrated human placental tissue portions of step (e) thereby forming the sterile human placental allograft. Also disclosed is a sterile human placental allograft produced by the method.

The present invention addresses the problem of providing a cryopreservation fluid for cells and a fluid for application to mammalian cells, capable of cryopreserving such cells and effectively suppressing cell death after thawing, as well as a method for cryopreserving mammalian cells using said fluid. Cell death after thawing can be suppressed more effectively than with conventional mammalian cell cryopreservation fluids when using an isotonic solution comprising: 2.0 to 6.0% (w / v) trehalose or a derivative thereof, or a salt of trehalose or a derivative thereof; 4.0 to 7.0% (w / v) dextran or a derivative thereof, or a salt of dextran or a derivative thereof; and DMSO or glycerin as the cryopreservation fluid for mammalian cells or as the fluid for application to mammalian cells, and the mammalian cells are cryopreserved in said fluid.

The invention discloses a preparation method of a compound preparation applied to eye diseases, which comprises the following steps: S1, mixing cleaned, dried and crushed chrysanthemum powder, erigeron breviscapus powder and pseudo-ginseng root powder according to a weight ratio of 10: (3-8): (1-5) to obtain compound powder, sieving with a 60-100-mesh sieve, adding deionized water according to a weight ratio of 1: (10-20), soaking in a water bath oscillator, and filtering with a filter screen to obtain filtrate; and then slightly boiling and decocting. The ophthalmic compound preparation prepared by the invention comprises basic components including a free amino acid extract, vitamin A ester, glycosaminoglycan, carboxymethyl chitosan and aminoethanesulfonic acid which are included by a compound hydrophilic polymer, and a gel matrix component consisting of polyglutamic acid and polygonatum polysaccharide, when the compound preparation is used, a specific buffer solution or an isotonic solution does not need to be adopted for dissolution, meanwhile, the prepared compound preparation for the eyes can improve the low adhesiveness of traditional eye washing liquid components, especially small molecule components, and the defects that traditional eye washing liquid is large in size, inconvenient to carry and poor in solution storage stability are overcome.

The present invention concerns the development of vesicles that could be used for generation of vaccines or as compound delivery vehicles. More specifically, the invention relates to a method for preparing a vesicle comprising the steps of: providing recombinant Trypanosoma brucei cells expressing sortaggable VSG, treating said cells in hypotonic solution in the presence of at least one protease inhibitor until the cells are lysed, isolating the cellular membranes from the solution, suspending the isolated membranes previously obtained in a isotonic solution, treating the suspended cellular membranes obtained in the previous step with sonication in order to obtain a vesicle suspension, removing aggregated membranous debris from the vesicle suspension previously obtained, separating the vesicle suspension into populations of vesicles, and providing vesicles from a population of vesicles which is characterized by the following parameters: (i) having a single predominant protein revealed after Coomassie staining an SDS PAGE that has an apparent molecular weight of 55 to 60 kDa, (ii) having a spherical appearance in electron micrographs and (iii) exhibiting a homogenous surface structure in electron micrographs. Moreover, the present invention also relates to a vesicle comprising sortaggable VSG characterized by the aforementioned parameters as well as such a vesicle for use in treating and / or preventing a disease or medical condition or as a compound delivery vesicle, preferably, drug delivery vehicle, more preferably, nucleic acid delivery vesicle. Finally, the invention contemplates a kit for carrying out the method of the present invention comprising recombinant Trypanosoma brucei cells expressing sortaggable VSG and at least one agent for carrying out the method of the present invention or a kit comprising the vesicle of the present invention.

The present invention relates to the development of vesicles that could be used for the production of vaccines or as compound delivery vehicles. More specifically, the present invention relates to a method for preparing vesicles comprising the steps of providing recombinant Trypanosoma brucei cells expressing a sortagable VSG, treating said cells in a hypotonic solution in the presence of at least one protease inhibitor until the cells are lysed, isolating cell membranes from the solution, suspending the isolated membranes already obtained in an isotonic solution, treating the suspended cell membranes obtained in the preceding step with sonication to obtain a vesicle suspension, removing aggregated membranous debris from the vesicle suspension already obtained, separating the vesicle suspension into a population of vesicles, and providing a vesicle from the population of vesicles characterized by the following parameters: (i) having a single predominant protein, revealed after Coomassie staining of SDS-PAGE, with an apparent molecular weight of 55-60 kDa, (ii) having a spherical appearance in electron micrographs, and (iii) showing a homogenous surface structure in electron micrographs. Furthermore, the present invention also relates to vesicles comprising sortagable VSG characterized by the above-mentioned parameters and to such vesicles for use in the treatment and / or prevention of a disease or medical condition or as a compound delivery vesicle, preferably a drug delivery vehicle, more preferably a nucleic acid delivery vesicle.Finally, the present invention contemplates a kit for performing the method of the present invention, comprising recombinant Trypanosoma brucei cells expressing a sortagable VSG and at least one agent for performing the method of the present invention or a kit comprising a vesicle of the present invention.

A stable AST-3424 injection preparation, being a solution containing 0.1-200 mg / ml or 1-200 mg / ml of AST-3424 active pharmaceutical ingredient. A solvent in the solution contains a C2-C8 monohydric alcohol. The preparation method comprises the following steps: subjecting the AST-3424 active pharmaceutical ingredient and a partial prescription volume of ethanol to a first dissolution and formulation; adding a prescription volume of propylene glycol for a second dissolution and formulation; and then adding the remaining prescription volume of ethanol for mixing and dissolving to obtain a solution containing 1-200 mg / ml of AST-3424 active pharmaceutical ingredient. Provided is an AST-3424 injection for injection, wherein the solvent is water, a glucose solution, ethanol, or propylene glycol, the solutes consist of the AST-3424 active pharmaceutical ingredient, an isotonic regulator, and a pH regulator. The concentration of the AST-3424 active pharmaceutical ingredient of the injection is 0.001-1.000 mg / ml, the pH of the injection is 6.8-10.5, and the solution is an isotonic solution.

The application discloses a kind of liquid guide laser bone ablation devices and methods of multi-modal sensing fusion, the liquid guide laser bone ablation device includes: supply module, ablation module, detection module and main control module, supply module includes containing cavity and nozzle, nozzle is located at the bottom of containing cavity, the isotonic solution in containing cavity can be ejected by nozzle and be flushed with liquid beam flow to be ablated tissue.Ablation module includes pulsed laser, pulsed laser is used to emit ablation laser in liquid beam flow, and liquid beam flow guides ablation laser to remove to be ablated tissue.Detection module includes frequency-sweeping laser and balanced optical detector, frequency-sweeping laser is used to emit probe laser in liquid beam flow, and balanced optical detector is used to receive the surface scattering of to be ablated tissue probe laser, and is converted into electrical signal.Main control module is used to determine the phase change data generated by light-heat expansion of to be ablated tissue based on electrical signal, determines the ablation depth of to be ablated tissue and calculates temperature.Realize the deep hole ablation of low taper.

The invention discloses an injection preparation, compatible liquid medicine and a preparation method thereof. The injection preparation and the compatible liquid medicine provided by the invention meet the requirements of long-term clinical tests and commercial production and sales through tests. The injection preparation is a solution containing a compound shown in the formula I, and a solvent of the solution contains C2-C8 alcohol and can also contain other cosolvents or solubilizers. A preferable injection preparation is a mixed solution containing 10mg / ml of the compound shown in the formula (I), DMA, ELP and ethanol, DMA is a cosolvent, and ELP is a solubilizer. A solvent of the ready-to-use injection (compatible liquid medicine) of the compound shown in the formula (I) is water, solutes of the ready-to-use injection comprise the compound shown in the formula I, DMA, ELP, ethyl alcohol, an isotonic regulating reagent and a pH regulator, the concentration of the compound A in the injection is 0.016-1.10 mg / ml, the pH of the injection is 7.4, and the injection is an isotonic solution. In addition, the invention also discloses a preparation method of the injection preparation and the compatible liquid medicine thereof.

The invention discloses treprostinil multivesicular liposome for treating pulmonary arterial hypertension. The multivesicular liposome is prepared from an inner water phase, an oil phase and an outer water phase through a double emulsification method, the treprostinil is dissolved in the inner water phase; the oil phase comprises soybean lecithin, cholesterol, glyceryl trioleate and electronegative lipid; the inner water phase and the outer water phase are body fluid isotonic solutions. The treprostinil multivesicular liposome disclosed by the invention has good stability and high encapsulation efficiency, obviously reduces burst release effect, shows obvious slow release characteristic, is beneficial to prolonging in-vivo drug half-life period, and can realize 48-hour treatment, reduce administration frequency, simplify administration method and improve patient compliance through simple subcutaneous injection. After the treprostinil multivesicular liposome is injected once, the inflammatory reaction of the injection part can be eliminated within 7 days, and the treprostinil multivesicular liposome has good safety.

The present invention discloses a rehabilitation table, which includes a suspension liquid tank and a support assembly. The patient is immersed in the repair liquid in the suspension liquid tank. The repair liquid composed of components such as brine, albumin, collagen, and hyaluronic acid, or the skin tissue isotonic solution composed of components such as water, salt, glucose, protein, amino acid, enzyme, hormone, and cytokine is used as a carrier. The patient is immersed in the repair liquid and in a zero-gravity suspension state, minimizing the mechanical extrusion of the damaged skin tissue of the patient by the external environment, which is beneficial to the regeneration and recovery of the tissue, and at the same time avoiding the secondary injury to the patient caused by replacing gauze, dressings, etc. At the same time, the present invention also uses an air adding mechanism to introduce ozone into the repair liquid in the suspension liquid tank to further enhance the rehabilitation effect. The support assembly can provide a support function for the patient immersed in the suspension liquid tank, improving the working safety factor of the rehabilitation table.

A method of preparing sterile human placental allografts by providing a human placental tissue from a donor within 24 hours to 72 hours post-childbirth; removing any visible blood, blood clots, and / or blood components from the human placental tissue without scraping or scrubbing the human placental tissue to preserve structural integrity of the human placental tissue; washing the human placental tissue in an isotonic solution while maintaining the structural integrity of the human placental tissue; dehydrating the human placental tissue thereby forming the dehydrated human placental tissue; resizing the dehydrated human placental tissue into dehydrated human placental tissue portions having predetermined sizes; and sterilizing the dehydrated human placental tissue portions of step (e) thereby forming the sterile human placental allograft. Also disclosed is a sterile human placental allograft produced by the method.

The invention discloses an antigen and adjuvant co-delivery nanocapsule vaccine and a preparation method thereof. The preparation method comprises the following steps: dissolving the polycaprolactone, the polycaprolactone-polyetherimide block copolymer, the adjuvant oil phase and the fat-soluble immune activator in ethanol to obtain a mixed solution; and carrying out solvent exchange on the obtained mixed solution and an isotonic solution in which the antigen is dissolved so as to obtain the antigen and adjuvant co-delivered nanocapsule vaccine. The nanocapsule vaccine is simple and efficient in preparation scheme, adopts a biocompatible material and a green solvent, is green and free of toxic and side effects, and can be suitable for large-scale vaccine production process popularization. The nanocapsule vaccine can realize co-delivery of the oil phase adjuvant, the water-soluble antigen and the water-soluble antigen, improves the immune response effect, and has a good prospect in the field of vaccine research and development.

A method of preparing sterile human placental allografts by providing a human placental tissue from a donor within 24 hours to 72 hours post-childbirth; removing any visible blood, blood clots, and / or blood components from the human placental tissue without scraping or scrubbing the human placental tissue to preserve structural integrity of the human placental tissue; washing the human placental tissue in an isotonic solution while maintaining the structural integrity of the human placental tissue; dehydrating the human placental tissue thereby forming the dehydrated human placental tissue; resizing the dehydrated human placental tissue into dehydrated human placental tissue portions having predetermined sizes; and sterilizing the dehydrated human placental tissue portions of step (e) thereby forming the sterile human placental allograft. Also disclosed is a sterile human placental allograft produced by the method.

A method of preparing sterile human placental allografts by providing a human placental tissue from a donor within 24 hours to 72 hours post-childbirth; removing any visible blood, blood clots, and / or blood components from the human placental tissue without scraping or scrubbing the human placental tissue to preserve structural integrity of the human placental tissue; washing the human placental tissue in an isotonic solution while maintaining the structural integrity of the human placental tissue; dehydrating the human placental tissue thereby forming the dehydrated human placental tissue; resizing the dehydrated human placental tissue into dehydrated human placental tissue portions having predetermined sizes; and sterilizing the dehydrated human placental tissue portions of step (e) thereby forming the sterile human placental allograft. Also disclosed is a sterile human placental allograft produced by the method.